Industry News — Clinical Updates

Quantel’s Vitra PDT Platform Receives CE Mark Approval for Treatment of PCV and CSR

Quantel Medical (Clermont-Ferrand, France ) has received Conformité Européenne (CE) Mark approval for Vitra PDT for the treatment of polypoidal choroidal vasculopathy (PCV) and central serous retinopathy (CSR).

Quantel plans to begin commercializing the laser platform immediately in countries requiring CE registration.

PCV is reported to be prevalent in 20% to 50% of Asian patients with presumed neovascular age-related macular degeneration (AMD) and in 4% to 12% of caucasians. Studies have demonstrated excellent short-term efficacy of PDT for treating PCV.

Updated September 13, 2014